July 20 (Reuters) - Australian Competition and Consumer Commission (ACCC):
- ACL'S PROPOSED ACQUISITION OF HEALIUS RAISES CONCERNS
- HAS OUTLINED SIGNIFICANT PRELIMINARY COMPETITION CONCERNS WITH AUSTRALIAN CLINICAL LABS LIMITED’S PROPOSED ACQUISITION OF HEALIUS
- CONCERNED THAT PROPOSED ACQUISITION WOULD BE LIKELY TO SUBSTANTIALLY LESSEN COMPETITION IN AUSTRALIAN PATHOLOGY SERVICES MARKETS
- PROPOSED ACQUISITION WOULD COMBINE TWO OF TOP THREE PROVIDERS OF PATHOLOGY SERVICES, INCREASING CONCENTRATION IN ALREADY CONCENTRATED MARKETS
- ACCC INVITES SUBMISSIONS IN RESPONSE TO THE STATEMENT OF ISSUES BY 10 AUGUST 2023
- PRELIMINARY VIEW IS COMBINED ACL AND HEALIUS MAY BE ABLE TO INCREASE PRICES OR REDUCE SERVICE QUALITY IN BIDS FOR PUBLIC HOSPITAL TENDERS
(([email protected];))
Add to My Watchlist
What is My Watchlist?
